The success of trials that have shown net clinical benefits of antithrombotic drugs as well as
the increasing prevalence of cardiovascular diseases in an ageing population have led to …

There are many angles to consider in drug treatment of obese patients. On the one hand,
some specific weight loss drugs are available, on the other, several drugs are associated …

Aim Apixaban is an oral, direct, factor‐X a inhibitor approved for thromboprophylaxis in
patients who have undergone elective hip or knee replacement surgery and for prevention …

Aims To investigate the relationship between body mass index (BMI) and outcomes in
patients with atrial fibrillation (AF). Methods and results In the ENGAGE AF-TIMI 48 trial …

Randomized controlled trials (RCTs) are performed with the primary goal of understanding
the safety and efficacy of a new therapy in a selected group of patients. Even when evidence …

Bariatric surgery may alter the absorption, distribution, metabolism, or elimination
(disposition) of orally administered drugs via changes to the gastrointestinal tract anatomy …

Introduction Lower limb venous disease affects up to one half, and obesity up to one quarter,
of the adult population. Many people are therefore affected by, and present to health …

Background—Obesity and surgery are known risk factors for venous thromboembolism
(VTE), but there is limited information about the independent effects of obesity on the …

Background Emerging safety and efficacy data for rivaroxaban suggest traditional therapy
and rivaroxaban are comparable in the morbidly obese. However, real‐world data that …

Background and Purpose—Whether dabigatran is associated with different risks of
cardiovascular, bleeding events, and mortality from warfarin in Asian patients with …